Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Zyprexa Marketing Going “Back to Basics” With Focus On Efficacy

Executive Summary

Lilly is taking a "back to basics" approach on marketing for its atypical antipsychotic Zyprexa to grow U.S. market share

You may also be interested in...



Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

Zyprexa Sales Will Decline In Second Half; Symbyax Starts Slow

Lilly is focusing on increasing the trial rate for Symbyax among primary care physicians and psychiatrists to help build sales of the bipolar depression combination product

Related Content

Topics

UsernamePublicRestriction

Register

PS044289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel